NVAX Earnings Date: Nov 5, 2026 (Estimated) — Novavax, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is NVAX's next earnings date?
Novavax, Inc. (NVAX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.35 on revenue of $50.4M.
How did NVAX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Novavax, Inc. posted EPS of -$0.32 versus the -$0.38 estimate, a beat of 13.5%. Revenue was $56.7M against a $52.5M estimate. The stock's 1-day post-earnings move was +0.5%.
How much does NVAX stock move after earnings?
NVAX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.6% (up or down) in the day after earnings.
About Novavax, Inc.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.38 | -0.32 | +13.51% | $56.7M | ✅ Beat | +0.52% | +3.38% | +34.29% |
| 2026-05-06 | Q1 2026 | -0.23 | -0.06 | +73.91% | $139.5M | ✅ Beat | +15.56% | +18.77% | +25.80% |
| 2026-02-26 | Q4 2025 | -0.56 | 0.11 | +119.64% | $147.1M | ✅ Beat | +17.42% | +3.78% | -6.09% |
| 2025-11-06 | Q3 2025 | -0.96 | -0.48 | +50.00% | $70.4M | ✅ Beat | -1.30% | -6.37% | -10.14% |
| 2025-08-06 | Q2 2025 | -0.12 | 0.62 | +616.67% | $239.2M | ✅ Beat | +12.63% | +26.00% | +15.75% |
| 2025-05-08 | Q1 2025 | 0.19 | 2.93 | +1442.11% | $666.7M | ✅ Beat | +11.93% | +0.17% | +25.21% |
| 2025-02-27 | Q4 2024 | -0.51 | -0.51 | +0.00% | $88.3M | ➖ Inline | -3.55% | +7.79% | -0.82% |
| 2024-11-12 | Q3 2024 | -0.83 | -0.76 | +8.43% | $84.5M | ✅ Beat | -6.10% | -13.10% | -2.11% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $38.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Licensing, Royalties, and Other | 98.2% | $37.8M | — | — | — | — | — |
| Royalties and Other | 1.8% | $676K | — | $38.5M | $45.0M | — | — |
By region
Q2 FY26 · $56.7M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 67.8% | $38.4M | -80.6% | — | $39.4M | $198.2M | $56.8M |
| Rest of the World | 30.2% | $17.1M | -54.2% | $39.6M | $43.3M | $37.4M | $13.0M |
| Europe | 2.0% | $1.1M | -69.2% | $4.4M | $8.1M | $3.6M | $655K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.